Loading patent…
AssigneesNational Research Council of Canada, University of Ottawa
InventorsMiroslava Cuperlovic-Culf, Mohammad Sajjad Ghaemi, Irina Alecu, Steffany Bennett
Estimating the term…
The disclosure relates to methods for diagnosing, detecting or screening for COVID-19 in a subject. The method comprises measuring the concentration of at least two sphingolipids in a blood sample. The sphingolipids are selected from Cer(d18:1/16:0), Cer(d18:1/26:0), 1-O-nervonoyl-Cer(d18:1/18:2), HexCer(d18:1/22:0), Cer(d18:1/18:0) and PE-Cer(d18:1/24:0). The method further comprises determining a ratio of the concentration of the at least two sphingolipids and comparing the ratio with a reference value, wherein a differential between the ratio and the reference value is indicative that the subject has or likely has COVID-19. Also provided is a kit for use with the method disclosed herein.
A method of diagnosing, detecting or screening for coronavirus disease 2019 (COVID-19) in a subject, the method comprising:
(canceled)
(canceled)
(canceled)
A kit comprising internal standards for mass spectrometry analysis for quantification of two or more sphingolipids selected from Cer(d18:1/16:0), Cer(d18:1/26:0), 1-O-nervonoyl-Cer(d18:1/18:2), HexCer(d18:1/22:0), Cer(d18:1/18:0) and PE-Cer(d18:1/24:0), and optionally comprising calibration standards, quality controls, test samples for assay validation and/or instructions for use thereof.
Dependencies are inferred from the claim text.